Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
+$0.05 today
- Market cap
- $196.25M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
Volume 0.23M
Average 0.32M
GALT Interest Income
Income earned on cash, deposits, and investments held by the company.
Galectin Therapeutics Inc.NASDAQ: GALT
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income growth accelerates
Q1 FY2026 interest income of $36K rose 2.9% year over year, ahead of the -56.5% change in trailing-twelve-month interest income. Sequentially, it rose 38.5% from the prior quarter. Over 3 fiscal years it compounded at +34.3% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +2.9% holds above the trailing-twelve-month pace of -56.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 126K USD
- Year-over-year change
- -62.7%
- 4-year CAGR
- +154.6%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 126K | -62.7% |
| FY2024 | 2024-12-31 | 338K | +47.0% |
| FY2023 | 2023-12-31 | 230K | +342.3% |
| FY2022 | 2022-12-31 | 52K | +1633.3% |
| FY2021 | 2021-12-31 | 3K | — |
Interest Income vs competitors
How GALT compares with its peers on the latest reported figures
- GALT's LTM Mar 2026 interest income of $127K is the 9th highest of the 10 companies compared; the peer median is $6.23M.
- Its year-over-year change of -56.5% is the 5th highest of 7, against a peer median of -17.2%.
- Over three fiscal years its annual growth of +34.3% compares with a peer median of +46.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.81M | -9.0% | +39.8% | — | |
| LTM Mar 2026 | $9.04M | +57.4% | — | — | |
| LTM Mar 2026 | $8.9M | +23.5% | +38.0% | 24713.9% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $6.36M | — | +277.3% | — |
| LTM Mar 2026 | $6.23M | -25.3% | +52.7% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $4.29M | -63.1% | +318.1% | — |
| LTM Mar 2026 | $1.74M | — | — | 94.2% | |
| LTM Mar 2026 | $944K | -79.3% | +28.9% | — | |
| LTM Mar 2026 | $127K | -56.5% | +34.3% | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding GALT) | $6.23M | -17.2% | +46.2% | 12404.0% | |
Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.82M | 31.74M | 32.13M | 36.57M | 14.29M |
| Selling, General & Admin | 6.36M | 6.62M | 5.94M | 5.86M | 5.8M |
| Operating Expenses | 30.18M | 38.35M | 38.07M | 42.43M | 20.09M |
| Depreciation & Amortization | 41K | 32K | 33K | 37K | 53K |
| EBITDA | (30M) | (37.71M) | (38.24M) | (41.47M) | (23.45M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (30.18M) | (38.35M) | (38.07M) | (42.43M) | (20.09M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3K | 52K | 230K | 338K | 126K |
| Interest Expense | 489K | 1.03M | 2.79M | 5.54M | 7.33M |
| Other Income / Expenses | (348K) | (424K) | (2.99M) | (4.61M) | (10.75M) |
| Income Before Tax | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| EPS (Diluted) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| Weighted Avg Shares | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
| Weighted Avg Shares (Diluted) | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
Galectin Therapeutics Inc.
NASDAQ:GALT
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.